278 related articles for article (PubMed ID: 17878353)
1. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
Hu L; Wang T; Gocke AR; Nath A; Zhang H; Margolick JB; Whartenby KA; Calabresi PA
PLoS One; 2013; 8(1):e54267. PubMed ID: 23382885
[TBL] [Abstract][Full Text] [Related]
3. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
4. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
5. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
6. T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.
Fung-Leung WP; Edwards W; Liu Y; Ngo K; Angsana J; Castro G; Wu N; Liu X; Swanson RV; Wickenden AD
PLoS One; 2017; 12(1):e0170102. PubMed ID: 28107393
[TBL] [Abstract][Full Text] [Related]
7. Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling.
Hu L; Gocke AR; Knapp E; Rosenzweig JM; Grishkan IV; Baxi EG; Zhang H; Margolick JB; Whartenby KA; Calabresi PA
J Biol Chem; 2012 Jan; 287(2):1261-8. PubMed ID: 22110135
[TBL] [Abstract][Full Text] [Related]
8. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
9. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
10. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.
Gocke AR; Lebson LA; Grishkan IV; Hu L; Nguyen HM; Whartenby KA; Chandy KG; Calabresi PA
J Immunol; 2012 Jun; 188(12):5877-86. PubMed ID: 22581856
[TBL] [Abstract][Full Text] [Related]
11. Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions.
Chiang EY; Li T; Jeet S; Peng I; Zhang J; Lee WP; DeVoss J; Caplazi P; Chen J; Warming S; Hackos DH; Mukund S; Koth CM; Grogan JL
Nat Commun; 2017 Mar; 8():14644. PubMed ID: 28248292
[TBL] [Abstract][Full Text] [Related]
12. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.
Li Z; Liu WH; Han S; Peng BW; Yin J; Wu YL; He XH; Li WX
J Biol Chem; 2012 Aug; 287(35):29479-94. PubMed ID: 22761436
[TBL] [Abstract][Full Text] [Related]
14. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
15. [Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4+ T lymphocytes in multiple sclerosis].
Ren XT; Wu WP; Xu QG; Huang DH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1896-9. PubMed ID: 19040002
[TBL] [Abstract][Full Text] [Related]
16. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
17. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.
Koch Hansen L; Sevelsted-Møller L; Rabjerg M; Larsen D; Hansen TP; Klinge L; Wulff H; Knudsen T; Kjeldsen J; Köhler R
J Crohns Colitis; 2014 Nov; 8(11):1378-91. PubMed ID: 24793818
[TBL] [Abstract][Full Text] [Related]
18. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
19. Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome.
Xu R; Cao M; Wu X; Wang X; Ruan L; Quan X; Lü C; He W; Zhang C
Clin Immunol; 2012 Feb; 142(2):209-17. PubMed ID: 22169811
[TBL] [Abstract][Full Text] [Related]
20. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]